Interpace Biosciences, Inc.
IDXG
$1.14
-$0.03-2.56%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 21.88% | 35.44% | 9.21% | 4.55% | 21.28% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 21.88% | 35.44% | 9.21% | 4.55% | 21.28% |
| Cost of Revenue | 20.66% | 16.13% | 10.02% | 9.20% | -15.18% |
| Gross Profit | 22.35% | 51.51% | 8.72% | 1.56% | 45.44% |
| SG&A Expenses | 21.89% | 16.88% | -8.57% | 4.63% | 3.62% |
| Depreciation & Amortization | -- | -- | -- | -- | -91.48% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 21.11% | 14.25% | -4.01% | 2.71% | -6.80% |
| Operating Income | 24.27% | 12,006.25% | 171.27% | 29.48% | 1,640.85% |
| Income Before Tax | 45.44% | 360.69% | 436.34% | 32.72% | 240.66% |
| Income Tax Expenses | -260.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Earnings from Continuing Operations | 46.21% | 357.95% | 440.76% | 33.02% | 239.80% |
| Earnings from Discontinued Operations | -78.67% | 4.65% | 66.36% | -31.65% | 147.77% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 41.63% | 308.47% | 1,078.29% | 33.33% | 230.56% |
| EBIT | 24.27% | 12,006.25% | 171.27% | 29.48% | 1,640.85% |
| EBITDA | 24.49% | 788.84% | 95.29% | -10.18% | 412.90% |
| EPS Basic | 16.84% | 304.92% | 1,060.59% | 31.41% | 228.73% |
| Normalized Basic EPS | 42.42% | 356.33% | 428.72% | 30.79% | 248.47% |
| EPS Diluted | -89.83% | 304.99% | 1,108.21% | 30.43% | 228.07% |
| Normalized Diluted EPS | -87.37% | 354.62% | 425.78% | 30.32% | 248.21% |
| Average Basic Shares Outstanding | 1.75% | 1.71% | 1.51% | 1.46% | 1.43% |
| Average Diluted Shares Outstanding | 1,045.71% | 2.41% | 1.97% | 1.76% | 1.62% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |